BeiGene prices high on swollen IPO
Chinese biopharmaceutical company BeiGene has raised $158m from a Nasdaq IPO after increasing the size of the offer and pricing it at the top of guidance.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts